The Journal of Allergy and Clinical Immunology
Volume 118, Issue 3 , Pages 766-767 , September 2006

Nondisclosure of conflicts of interest is perilous to the advancement of science

References 

  1. Bush RK, Portnoy JM, Saxon A, Terr AI, Wood RA. The medical effects of mold exposure. J Allergy Clin Immunol. 2006;117:326–333
  2. National Institute for Occupational Safety and Health (NIOSH). Occupational respiratory disease surveillance, hypersensitivity pneumonitis. ICD-9 (1979-1999). Rubrics Code 495; ICD-10 (1999-Present) Rubrics Code J67; National Occupational Respiratory Mortality Surveillance, “Non-paid worker or non-worker or own home/at home” and “Elementary and secondary schools” – two of the ten industries/settings with the most frequent deaths reported as a result of Hypersensitivity Pneumonitis (HP). ICD-9 Rubrics Code 495 (1979-1999). Available at: http://webappa.cdc.gov/ords/norms-icd.html. Accessed July 26, 2006.
  3. Hardin BD, Kelman BJ, Saxon A, ACOEM Council on Scientific Affairs. ACOEM policies and position statements evidence based statements, adverse human health effects associated with molds in the indoor environment. Available at: http://www.acoem.org/guidelines/article.asp?ID-52. Accessed July 26, 2006.
  4. Robbins CA, Swenson LJ, Nealley ML, Kelman BJ, Gots RE. Health effects of mycotoxins in indoor air: a critical review. Appl Occup Environ Hyg. 2000;15:773–784
  5. Rand TG, Giles S, Flemming J, Miller DJ, Puniani E. Inflammatory and cytotoxic responses in mouse lungs exposed to purified toxins from building isolated Penicillium. Toxicol Sci. 2005;87:213–222
  6. Robbins CA, Swenson IJ, Hardin BD. Risks from inhaled mycotoxins in indoor office and residential environments. Int J Toxicol. 2004;23:3–10
  7. Bennett JW, Klich M. Mycotoxins. Clin Microbiol Rev. 2003;16:497–516
  8. Terr AI. Toxic mold disease: a diagnosis of litigation. Ann Allergy Asthma Immunol. 2005;95:239–246
  9. Pietrykowski M. Proposed causal connection between inhalation of indoor molds and severe health maladies is “weak and unproven” according to Medical Association. Mold…matters! 2003;3:5. Available at: http://www.gordonrees.com/pubs/pdf/mold_mat_janfeb_03.pdf. Accessed July 26, 2006.

 Disclosure of potential conflict of interest: K. H. Kilburn has served as an expert witness in mold litigation primarily retained by the plaintiff bar and is president of Neuro-Test, Inc. M. Gray has served as an expert witness in mold litigation primarily retained by the plaintiff bar, is sole proprietor of ImmunoTox, and has a patent pending with Realtime Laboratories. S. Kramer has been a party in mold litigation represented by the plaintiff bar, volunteers to assist those made ill from mold, and is a real estate agent by profession.

PII: S0091-6749(06)01398-4

doi: 10.1016/j.jaci.2006.07.009

The Journal of Allergy and Clinical Immunology
Volume 118, Issue 3 , Pages 766-767 , September 2006

Article Tools